Australia’s Therapeutic Goods Administration is consulting on stronger labeling requirements for listed medicines containing vitamin B6 to address peripheral neuropathy risks.
High or built-up consumption of vitamin B6 raises the likelihood of peripheral neuropathy, a condition that can cause intense, disabling, and potentially enduring harm to the nerves. At present, items containing vitamin B6 that supply a daily pyridoxine equivalent greater than 10 mg are required to instruct buyers to discontinue use and consult a medical professional if they develop numbness, burning, or tingling sensations.
As part of its broader supervision of vitamin B6, the agency is now looking to make its cautionary notices more stringent. This comes after its ruling that, beginning in June 2027, every vitamin B6 supplement suggesting a daily intake ranging from above 50 mg up to 200 mg must be strictly categorized as a pharmacist-only (Schedule 3) item.
The TGA has proposed three options for strengthening the warning statements of vitamin B6 supplements and has opened a public consultation, which closes on Nov. 25. The proposal covers pyridoxine hydrochloride, pyridoxal 5-phosphate and pyridoxal 5-phosphate monohydrate (9-5-P).
Portfolio Exposure Across Multiple Formulas
Shoppers can inadvertently build up their vitamin B6 levels by taking sports-nutrition items, stress supplements, energy formulas, magnesium products, and multivitamins simultaneously without realizing the total amount consumed.
Consequently, makers of these goods must audit the overall daily intake levels across their entire product lines, accounting for alternative names for the ingredient like P-5-P and pyridoxine.
Consumer Spending Shifts in Wellness Markets
Consumers have more wellness products to choose from than ever, but many remain dissatisfied with retail options regarding longevity, mental health and mobility. McKinsey & Company’s Future of Wellness 2027 report found that US consumers placed effectiveness on equal footing with price, followed by quality.
Among the biggest wellness spenders, effectiveness and quality ranked ahead of cost. McKinsey divided these consumers into maximalist optimizers and confident enthusiasts, who accounted for 35% of wellness consumers but 55% of spending.
Warning Statement Options for Vitamin B6 Supplements
What specific vitamin B6 forms are covered by the TGA proposal?
The proposal covers pyridoxine hydrochloride, pyridoxal 5-phosphate and pyridoxal 5-phosphate monohydrate (9-5-P). The public consultation on the three warning statement options closes on Nov. 25.
When does the pharmacist-only reclassification take effect?
Effective June 2027, the TGA has ordered that any vitamin B6 supplement suggesting a daily intake of more than 50 mg and up to 200 mg must be restricted to pharmacist-only (Schedule 3) status.
Related reading